GlaxoSmithKline: ViiV Healthcare Reports Positive HIV Trial Results
22 August 2019 - 5:10PM
Dow Jones News
By Ian Walker
GlaxoSmithKline PLC's (GSK.LN) joint-venture company ViiV
Healthcare said Thursday that a global phase 3 "Atlas-2M" study of
rilpivirine for the treatment of HIV met its primary endpoint.
ViiV Healthcare--which is jointly owned by Pfizer Inc.
(PFE)--said the study showed a combination of cabotegravir and
rilpivirine administered every eight weeks is similar to a
four-week administration.
"The Atlas-2M study results mean that people living with HIV
could maintain viral suppression with six total treatments per
year, instead of a daily oral treatment 365 times per year," Viiv
Healthcare's Head of Research & Development Kimberly Smith
said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
August 22, 2019 02:55 ET (06:55 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024